Literature DB >> 10793179

Achieving tissue-level perfusion in the setting of acute myocardial infarction.

D Mukherjee1, D J Moliterno.   

Abstract

Treatment for ST-elevation myocardial infarction (MI) has advanced rapidly in the last few years with improvements in early fibrinolytic therapy, primary percutaneous revascularization, and use of potent platelet glycoprotein IIb/IIIa inhibitors. It is now obvious that establishing epicardial patency after myocardial infarction is not synonymous with tissue-level perfusion. Techniques and therapies are now available that measure true tissue-level perfusion and that may improve tissue-level perfusion after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793179     DOI: 10.1016/s0002-9149(00)00818-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Primary percutaneous coronary intervention versus thrombolytic treatment: long term follow up according to infarct location.

Authors:  J P S Henriques; F Zijlstra; A W J van 't Hof; M-J de Boer; J-H E Dambrink; A T M Gosselink; J C A Hoorntje; J P Ottervanger; H Suryapranata
Journal:  Heart       Date:  2005-04-14       Impact factor: 5.994

2.  The relationship of intracoronary stent placement following thrombolytic therapy to tissue level perfusion.

Authors:  C Michael Gibson; Daniel Frisch; Sabina A Murphy; Steven G Gourlay; Raymond Gibbons; Kenneth W Baran; Michel Nguyen; Sebastian Palmeri; Hal V Barron
Journal:  J Thromb Thrombolysis       Date:  2002-04       Impact factor: 2.300

3.  Interventional Strategies in Thrombus Management for ST Elevation Myocardial Infarction.

Authors:  Michael Tsang; Sanjit Jolly
Journal:  Interv Cardiol       Date:  2015-03

Review 4.  Prognostic Value of Myocardial Blush Grade in ST-elevation MI: A Systematic Review and Meta-analysis.

Authors:  Patrick Vera Cruz; Patricio Palmes; Nadine Bacalangco
Journal:  Interv Cardiol       Date:  2022-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.